Maze Therapeutics (MAZE) said late Thursday it priced its upsized initial public offering of about 8.8 million shares at $16 per share for gross proceeds of $140 million.

In addition, Maze Therapeutics said it has granted the underwriters a 30-day option to purchase up to an additional 1.3 million shares of common stock at the initial public offering price, less underwriting discounts and commissions.

The shares are expected to begin trading on the Nasdaq on Friday under the symbol 'MAZE.'

The offering is expected to close on Monday.